Alnylam Pharmaceuticals | ALNY - 销售成本



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 31.05B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


销售成本 更改 日
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Moderna USD 93M 862M 2026-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.46B 83M 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.14B 618M 2026-03
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Takeda JPY 517.6B 42.94B 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06
Xencor USD 61.66M 50.95M 2025-06